| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/23/2013 | CA2536518C Proteasome inhibitors and methods of using the same |
| 07/23/2013 | CA2493878C Parenteral formulations containing a rapamycin hydroxyester |
| 07/23/2013 | CA2471968C Immunostimulatory nucleic acids and use thereof |
| 07/23/2013 | CA2357950C Therapeutic phosphodiesterase inhibitors |
| 07/19/2013 | WO2012097313A2 Therapeutic antibodies against ror-1 protein and methods for use of same |
| 07/19/2013 | CA2858350A1 Therapeutic antibodies against ror-1 protein and methods for use of same |
| 07/18/2013 | WO2013106824A1 Epherin receptor targeting agents |
| 07/18/2013 | WO2013106812A1 Personalized medicine for the prediction of therapy targeting the hedgehog pathway |
| 07/18/2013 | WO2013106792A1 Heterocyclic compounds and uses as anticancer agents. |
| 07/18/2013 | WO2013106774A1 Cancer-specific suicide gene for cell-based and gene therapy |
| 07/18/2013 | WO2013106702A1 Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions |
| 07/18/2013 | WO2013106647A1 Supercritical guggul extracts and uses thereof |
| 07/18/2013 | WO2013106646A2 Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
| 07/18/2013 | WO2013106485A2 Ultralong complementarity determining regions and uses thereof |
| 07/18/2013 | WO2013106175A1 Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
| 07/18/2013 | WO2013105895A1 A pharmaceutical composition comprising stable, amorphous hybrid nanopraticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component |
| 07/18/2013 | WO2013105665A1 Collagen structure, and method for producing collagen structure |
| 07/18/2013 | WO2013105037A1 Inhibitors of p53-mdm2 interaction |
| 07/18/2013 | WO2013104933A1 3,3-diphenyl-n-(1-phenylethyl) propan-1 -amine : as a new selective ligand of the sigma-1 receptors, with anti-apoptotic (cytoprotective) properties and prototypical anticancer activity |
| 07/18/2013 | WO2013104871A1 Composition containing agmatine, and uses thereof in preparing drugs or neutraceutical substances |
| 07/18/2013 | WO2013104831A1 Arylamide derivatives having antiandrogenic properties |
| 07/18/2013 | WO2013104829A1 Novel arylamide derivatives having antiandrogenic properties |
| 07/18/2013 | WO2013104611A1 Substituted pyrazolopyrimidines as akt kinase inhibitors |
| 07/18/2013 | WO2013104610A1 Substituted imidazopyrazines as akt kinase inhibitors |
| 07/18/2013 | WO2013104575A1 Thienopyrimidine compounds |
| 07/18/2013 | WO2013104263A1 Synthesis of polyhydroxy benzopyran ketone compound and anti-tumor effect thereof |
| 07/18/2013 | WO2013104050A2 Method for treating breast cancer |
| 07/18/2013 | WO2013071068A3 Treatment of hematologic malignancies with an anti-cxcr4 antibody |
| 07/18/2013 | WO2013070852A3 Compounds and compositions used to epigenetically transform cells and methods related thereto |
| 07/18/2013 | WO2013049279A3 Nitrogen mustard derivatives |
| 07/18/2013 | WO2013037943A8 Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors |
| 07/18/2013 | WO2013021105A3 Novel derivatives of furanones and pharmaceutical composition containing same |
| 07/18/2013 | US20130184333 Growth factor isoform |
| 07/18/2013 | US20130184325 Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
| 07/18/2013 | US20130184242 Pharmaceutical Composition for Topical Application |
| 07/18/2013 | US20130184221 Kinase Inhibitors And Uses Thereof |
| 07/18/2013 | US20130184214 Pharmaceutical compositions and methods |
| 07/18/2013 | US20130183326 Methods and compositions for modulating the activity of the interleukin-35 receptor complex |
| 07/18/2013 | US20130183318 Methods and compositions for the inhibition of stat5 in prostate cancer cells |
| 07/18/2013 | US20130183271 Methods and Compositions Concerning Poxviruses and Cancer |
| 07/18/2013 | US20130181107 Furnace mount and method of installation |
| 07/18/2013 | CA2860999A1 Synthesis of polyhydroxy chromenone compounds and their anti-tumor effects |
| 07/18/2013 | CA2860932A1 A pharmaceutical composition comprising stable, amorphous hybrid nanopraticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component |
| 07/18/2013 | CA2857400A1 Method for treating breast cancer |
| 07/18/2013 | CA2851827A1 Nanoparticles for controlling bleeding and drug delivery |
| 07/18/2013 | CA2832596A1 Taxane and abeo-taxane analogs |
| 07/17/2013 | EP2615115A2 Antigen-binding constructs |
| 07/17/2013 | EP2615101A1 Nucleoside derivatives, synthesis methods and uses thereof for preparing anti-tumor and anti-virus medicaments |
| 07/17/2013 | EP2615100A1 Fructosylated puerarin, and preparation method therefor and use thereof |
| 07/17/2013 | EP2615092A1 Heterocyclic amino berbamine derivatives, preparation method and use thereof |
| 07/17/2013 | EP2615091A2 Solid forms comprising 4-[9-(3S)-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9H-purin-2-ylamino]-trans-cyclohexan-1-ol, compositions thereof, and uses therewith |
| 07/17/2013 | EP2614839A2 Method for using BOC/CDO to modulate hedgehog signaling |
| 07/17/2013 | EP2614837A1 Anti-VEGF antibody compositions and methods |
| 07/17/2013 | EP2614369A2 Inhibitors of human ezh2, and methods of use thereof |
| 07/17/2013 | EP2614146A1 Ttll4 peptides and vaccines containing the same |
| 07/17/2013 | EP2614084A2 Anti-human folate receptor beta antibodies and methods of use |
| 07/17/2013 | EP2614082A1 4-1bb binding molecules |
| 07/17/2013 | EP2614080A1 Phosphorylated twist1 and metastasis |
| 07/17/2013 | EP2614065A1 Substituted pyrazolo-quinazoline derivatives as kinase inhibitors |
| 07/17/2013 | EP2614063A1 Substituted imidazopyridazines |
| 07/17/2013 | EP2614051A2 P53-mdm2 antagonists |
| 07/17/2013 | EP2613810A1 Biodegradable, water soluble and ph responsive poly(organo)phosphazenes |
| 07/17/2013 | EP2613808A1 Companion animal treatments |
| 07/17/2013 | EP2613791A2 Somatostatin receptor-based cancer therapy |
| 07/17/2013 | EP2613789A1 Sdf-1 binding nucleic acids and the use thereof in cancer treatment |
| 07/17/2013 | EP2613782A2 Indazole derivatives useful as erk inhibitors |
| 07/17/2013 | EP2613773A2 Airway administration of angiogenesis inhibitors |
| 07/17/2013 | EP2044961B1 Phospholipid analogues for the treatment of pancreatic, ovarian and colon cancers, melanomas, gliomas, and carcinosarcomas |
| 07/17/2013 | CN1674929B Use of protein kinase N beta |
| 07/17/2013 | CN103209997A High purity heparin and production method therefor |
| 07/17/2013 | CN103209983A Crystalline form of 13-[(n-tert-butoxycarbonyl)-2'-o-hexanoyl-3-phenylisoserinyl]-10-deacetylbaccatin III |
| 07/17/2013 | CN103209982A Novel compound of a reverse-turn mimetic and a production method and use therefor |
| 07/17/2013 | CN103209702A Anticancer composition containing GKN 1 |
| 07/17/2013 | CN103209701A Immunogenic vaccine |
| 07/17/2013 | CN103209696A Methods of enhancing antibody-dependent cellular cytotoxicity |
| 07/17/2013 | CN103209691A Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor |
| 07/17/2013 | CN103209690A Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor |
| 07/17/2013 | CN103205487A Method and detection reagent for prediction of prostate cancer susceptibility |
| 07/17/2013 | CN103205486A Method and reagent for prediction of susceptibility of prostate cancer |
| 07/17/2013 | CN103205407A Extended soluble ph20 polypeptides and uses thereof |
| 07/17/2013 | CN103205400A Recombinant lentiviral vector containing ubiquitin-specific protease gene USP39-shRNA (short hairpin ribonucleic acid) and application thereof |
| 07/17/2013 | CN103205399A Recombinant herpes simplex virus, and preparation method and application thereof |
| 07/17/2013 | CN103205258A Gold nano-star @ quantum dot composite cell probe with photothermal and fluorescence enhancement dual-functions and preparation method and applications thereof |
| 07/17/2013 | CN103204997A Preparation method of polyactic acid/polyethylene glycol biological hybrid material for PDT (photodynamic therapy) |
| 07/17/2013 | CN103204981A Method for synthesizing polylactic acid-block-polyN-isopropyl acrylamide temperature-sensitive material |
| 07/17/2013 | CN103204935A Modified Antigen Binding Molecules With Altered Cell Signaling Activity |
| 07/17/2013 | CN103204934A Cytotoxicity Mediation Of Cells Evidencing Surface Expression Of Cd44 |
| 07/17/2013 | CN103204931A Human Monoclonal Antibodies To Fucosyl-gm1 And Methods For Using Anti-fucosyl-GM1 |
| 07/17/2013 | CN103204921A Secretory protein with chemotactic activity, and coding sequence and application thereof |
| 07/17/2013 | CN103204908A MTA1-derived anti-tumour CTL (cytotoxiclymphocyte) epitope peptide and application thereof |
| 07/17/2013 | CN103204907A Raja porosa cartilage polypeptide angiogenesis inhibitory factor, and preparation method and application thereof |
| 07/17/2013 | CN103204904A Dasyatis akajei chondroprotein polypeptide capable of resisting prostate cancer, and preparation method and application thereof |
| 07/17/2013 | CN103204901A Preparation method for bifunctional conjugate |
| 07/17/2013 | CN103204898A Anticancer compound and application thereof |
| 07/17/2013 | CN103204897A Site 3, 12 modified soladulcidine derivative, its preparation method, preparation and medical use thereof |
| 07/17/2013 | CN103204896A 12-oxosoladulcidine amino acid conjugate, its preparation method, preparation and medical application |
| 07/17/2013 | CN103204892A Beta-norcholest-6-(4'-phenyl)-aminothizone compound and synthesis method and application thereof in preparing antitumor drug |
| 07/17/2013 | CN103204862A 6-phenylimidazol[2, 1-b]thiazole-3-amide derivative, its preparation method and application |
| 07/17/2013 | CN103204861A Fluoro-substituted triptolide derivative, its preparation method and application |
| 07/17/2013 | CN103204855A Compound I tetrazole (1, 5-a) pyrimidine-5, 7-diol and synthetic route thereof |